Pharmacokinetic and exposure–response analyses of pertuzumab in combination with trastuzumab and docetaxel during neoadjuvant treatment of HER2+ early breast cancer
详细信息 查看全文
- 作者：Angelica L. Quartino ; Hanbin Li ; Jin Y. Jin…
- 关键词：Pertuzumab ; Exposure–response ; Pharmacokinetics ; Early breast cancer ; HER2 ; Neoadjuvant
- 刊名：Cancer Chemotherapy and Pharmacology
- 出版年：2017
- 出版时间：February 2017
- 年：2017
- 卷：79
- 期：2
- 页码：353-361
- 全文大小：621KB
- 刊物类别：Biomedical and Life Sciences
- 刊物主题：Oncology; Pharmacology/Toxicology; Cancer Research;
- 出版者：Springer Berlin Heidelberg
- ISSN：1432-0843
- 卷排序：79
文摘
PurposeThe NeoSphere trial evaluated pertuzumab in the neoadjuvant setting [early breast cancer (EBC)] with pathological complete response (pCR) as the primary efficacy end point. This analysis of pertuzumab aimed to (1) compare its pharmacokinetics (PK) in patients with EBC versus advanced cancers, (2) to further evaluate PK drug–drug interactions (DDIs) when given in combination with trastuzumab, and (3) to assess the relationship between exposure and efficacy to assess the clinical dosing regimen in the EBC patients.